SpectraCure AB
SpectraCure AB (publ) engages in the development of cancer treatment system in Sweden. It develops Q-PRO, a laser unit; IDOSE software platform, which calculates the optimal laser light dose and placement of the optical fibers; and disposable items comprising needles, optical fibers, and light-sensitive medication. The company was incorporated in 2003 and is based in Lund, Sweden.
SpectraCure AB (SPEC) - Net Assets
Latest net assets as of December 2025: Skr93.55 Million SEK
Based on the latest financial reports, SpectraCure AB (SPEC) has net assets worth Skr93.55 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr104.47 Million) and total liabilities (Skr10.92 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr93.55 Million |
| % of Total Assets | 89.55% |
| Annual Growth Rate | 29.46% |
| 5-Year Change | -46.75% |
| 10-Year Change | 323.18% |
| Growth Volatility | 132.06 |
SpectraCure AB - Net Assets Trend (2013–2025)
This chart illustrates how SpectraCure AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SpectraCure AB (2013–2025)
The table below shows the annual net assets of SpectraCure AB from 2013 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr93.55 Million | -12.45% |
| 2024-12-31 | Skr106.86 Million | -17.71% |
| 2023-12-31 | Skr129.86 Million | -13.60% |
| 2022-12-31 | Skr150.30 Million | -14.45% |
| 2021-12-31 | Skr175.68 Million | -10.92% |
| 2020-12-31 | Skr197.22 Million | +124.68% |
| 2019-12-31 | Skr87.78 Million | +35.21% |
| 2018-12-31 | Skr64.92 Million | +384.10% |
| 2017-12-31 | Skr13.41 Million | -39.34% |
| 2016-12-31 | Skr22.11 Million | +69.30% |
| 2015-12-31 | Skr13.06 Million | +519.80% |
| 2014-12-31 | Skr-3.11 Million | -173.68% |
| 2013-12-31 | Skr4.22 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to SpectraCure AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20934599400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr40.97 Million | 43.79% |
| Other Components | Skr268.03 Million | 286.51% |
| Total Equity | Skr93.55 Million | 100.00% |
SpectraCure AB Competitors by Market Cap
The table below lists competitors of SpectraCure AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Witbe Net SA
PA:ALWIT
|
$3.21 Million |
|
Caely Holdings Bhd
KLSE:7154
|
$3.21 Million |
|
Suparma Tbk
JK:SPMA
|
$3.21 Million |
|
i2S SA
PA:ALI2S
|
$3.21 Million |
|
Polychem Indonesia Tbk
JK:ADMG
|
$3.21 Million |
|
Top Gum Industries Ltd
TA:TPGM
|
$3.21 Million |
|
Tuktu Resources Ltd.
V:TUK
|
$3.21 Million |
|
Clientele
JSE:CLI
|
$3.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SpectraCure AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 106,856,000 to 93,550,000, a change of -13,306,000 (-12.5%).
- Net loss of 56,079,000 reduced equity.
- Other factors increased equity by 42,773,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-56.08 Million | -59.95% |
| Other Changes | Skr42.77 Million | +45.72% |
| Total Change | Skr- | -12.45% |
Book Value vs Market Value Analysis
This analysis compares SpectraCure AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.41x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.26x to 0.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | Skr0.07 | Skr0.09 | x |
| 2014-12-31 | Skr-0.19 | Skr0.09 | x |
| 2015-12-31 | Skr0.36 | Skr0.09 | x |
| 2016-12-31 | Skr0.73 | Skr0.09 | x |
| 2017-12-31 | Skr0.23 | Skr0.09 | x |
| 2018-12-31 | Skr0.83 | Skr0.09 | x |
| 2019-12-31 | Skr1.06 | Skr0.09 | x |
| 2020-12-31 | Skr2.13 | Skr0.09 | x |
| 2021-12-31 | Skr1.81 | Skr0.09 | x |
| 2022-12-31 | Skr1.55 | Skr0.09 | x |
| 2023-12-31 | Skr1.34 | Skr0.09 | x |
| 2024-12-31 | Skr1.10 | Skr0.09 | x |
| 2025-12-31 | Skr0.23 | Skr0.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SpectraCure AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -59.95%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.12x
- Recent ROE (-59.95%) is below the historical average (-59.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -469.29% | -384.67% | 0.23x | 5.38x | Skr-5.85 Million |
| 2014 | 0.00% | -912.64% | 0.09x | 0.00x | Skr-4.03 Million |
| 2015 | -45.07% | -755.89% | 0.06x | 1.08x | Skr-7.19 Million |
| 2016 | -28.82% | -3685.20% | 0.01x | 1.30x | Skr-8.58 Million |
| 2017 | -64.85% | -3358.38% | 0.02x | 1.10x | Skr-10.04 Million |
| 2018 | -14.80% | -1612.42% | 0.01x | 1.06x | Skr-16.10 Million |
| 2019 | -15.59% | -1793577.98% | 0.00x | 1.14x | Skr-22.46 Million |
| 2020 | -7.81% | -1272254.34% | 0.00x | 1.07x | Skr-35.13 Million |
| 2021 | -13.29% | -406.00% | 0.03x | 1.08x | Skr-40.91 Million |
| 2022 | -16.85% | -4698.70% | 0.00x | 1.08x | Skr-40.36 Million |
| 2023 | -15.74% | -6427.99% | 0.00x | 1.12x | Skr-33.43 Million |
| 2024 | -21.53% | -117.78% | 0.16x | 1.13x | Skr-33.69 Million |
| 2025 | -59.95% | 0.00% | 0.00x | 1.12x | Skr-65.43 Million |
Industry Comparison
This section compares SpectraCure AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $75,200,026
- Average return on equity (ROE) among peers: -74.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SpectraCure AB (SPEC) | Skr93.55 Million | -469.29% | 0.12x | $3.21 Million |
| Acarix A/S (ACARIX) | $76.60 Million | -60.65% | 0.08x | $28.86 Million |
| Arcoma AB (ARCOMA) | $12.52 Million | -92.85% | 4.66x | $8.93 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $353.18 Million | -39.18% | 0.87x | $19.20 Million |
| CellaVision AB (CEVI) | $20.07 Million | 13.08% | 1.20x | $262.59 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $65.69 Million | -72.50% | 0.20x | $13.78 Million |
| Chordate Medical Holding AB (CMH) | $38.95 Million | -55.88% | 0.13x | $17.64K |
| Coala Life Group AB (COALA) | $52.33 Million | -287.99% | 0.53x | $468.93K |
| C-Rad AB (publ) (CRAD-B) | $93.64 Million | 22.63% | 0.57x | $56.67 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $34.43K |
| Episurf Medical AB (publ) (EPIS-B) | $41.40 Million | -170.53% | 0.39x | $5.40 Million |